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Abstract 
Aims: The aim of this observational study is to investigate the relationship 
between age, duration of diabetes, HbA1c and the parameters of glucose 
levels measured with real-time CGM in children with type 1 diabetes. 
Methods: Glucose level was characterized with the relative time spent in 
hyper- and hypoglycemia, central tendency, variability and MAGE during 
(real-time) CGM. These parameters were measured in 57 children with type 
1 diabetes mellitus. The univariate association of the measured parameters 
was investigated with scatterplots as well as with linear and distance 
correlation coefficients. 
Results: Age and duration of diabetes was not clinically relevantly 
associated with any descriptor of glucose level. HbA1c had an overall 
positive association with variability and MAGE observed during CGM. 
Slight, but non-significant, positive association of HbA1c was observed 
with the time spent in hyperglycemia and the central tendency of glucose 
level. With the exception of MAGE, the associations of the descriptors with 
HbA1c are non-monotonic, with a temporary break in the positive 
correlation at 10%. 
Conclusions: The results confirmed the well-known positive association of 
HbA1c with the central tendency of glucose level. The non-monotonic 
relationship between HbA1c and the indicators of the central tendency of 
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glucose level might be caused by the varying adherence of the patients 
during the CGM registration. HbA1c’s positive association with MAGE 
without that non-monotonicity underlines MAGE’s usefulness in the 
reliable assessment of the patients’ glycemic state. 
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Type 1 diabetes is one of the most common chronic disorders in children 
and adolescents. Several factors play a role in the pathogenesis of the 
complications in diabetes. Improved metabolic control in particular might 
prevent or postpone late vascular complications, as has been demonstrated 
by many studies, mainly by the Diabetes Control and Complications Trial 
[1] as well as by Epidemiology of Diabetes Interventions and Complications 
[2]. Glycemic control is usually determined by measurement of glycated 
hemoglobin (HbA1c). However, patients with similar glycated hemoglobin 
levels and mean glucose values can experience different glycemic 
fluctuations. Evidence implicates glycemic variability, mostly present in the 
form of postprandial glycemic spikes, as a key factor in the development of 
the complications of diabetes [3]. 
New technological improvements, especially continuous glucose monitoring 
(CGM) technique, which consists of a disposable transcutaneous glucose 
sensor along with an electronic transmitter/receiver unit [4], allows a more 
precise follow-up of the glucose evolution in vivo. Monitoring might be 
blinded to the patient which is used to inform healthcare professionals about 
the patient’s glucose evolution, or non-blinded, also called personal or real-
time CGM (RT-CGM), where the receiver is supplemented with a graphical 
display which allows the patients to have a direct, almost minute-to-minute 
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observation of their own glucose level, thus enabling a better management 
of their diabetes. This has demonstrated to improve glucose control [5-6]. 
By their 5 minutes measurement frequency (288 measurements per day) the 
possibilities of CGM have direct effect on short term monitoring, but 
questions are raised on its usefulness for evaluating long-term outcome. The 
most important classical indicator in this sense is HbA1c that reflects the 
average glucose level of a patient over 120 days (the “life cycle” of red 
blood cells) [7]. Beside HbA1c, glycemic variability is now suggested to 
play role in the appearance of long-term complications of diabetes [8-9]. 
Correlation of HbA1c and glucose itself is well known, but CGM opened 
new horizons in a more thorough investigation of this issue [10-12]. The 
aim of the current work is to evaluate the relationship between age, duration 
of diabetes and HbA1c on the one hand, and glycemia measured with CGM 
on the other hand in children with type 1 diabetes. 
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2. Material and methods 
2.1. Study population and design 
Fifty seven children with type 1 diabetes mellitus (DM) were selected as a 
convenience sample from the database of the 1st Department of Paediatrics 
of Semmelweis University (Budapest, Hungary), with CGM measurement 
data between July 2009 and February 2011. Only patients with at least 1 
year of DM duration were included so that even HbA1c had time to reach its 
characteristic levels. 
The vast majority of the patient were poorly controlled (according to the 
guidelines [13] of the American Diabetes Association and the International 
Society for Pediatric and Adolescent Diabetes [14-16]) with CGM 
performed to optimize therapy. CGM measurements were non-blinded to 
the patients, i.e. real time (RT)-CGM was employed. 
The sample included patients using continuous subcutaneous insulin 
infusion (CSII) and multiple daily injections (MDI) treatment regimes. The 
CGM sensors were accurate and reliable, time to sensor failure, frequency 
and duration of data gaps were negligible, the alarms worked properly. Sex, 
age, duration of diabetes and HbA1c at the time of the CGM measurement 
were extracted for each patient from the electronic records of the hospital 
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information system. HbA1c was measured with NGSP certified method. 
The summary of these patient characteristics is shown in Table 1. 
CGM recordings were electronically processed (by exporting them to 
comma separated values format using the software of the device 
manufacturer) and the following parameters were extracted from the time 
series of glucose measurements to characterize the clinically relevant 
aspects of the patients’ glucose evolution: 
 Time spent in hyperglycemia and hypoglycemia relative to the 
whole length of recording (hypoglycemia was defined as glucose 
level < 3.9 mmol/l, hyperglycemia was defined as glucose level > 10 
mmol/l) in [%]. 
 Central tendency of glucose levels (quantified with mean and 
median glucose level) in [mmol/l]. 
 Dispersion, i.e. variability of glucose levels (quantified with standard 
deviation and interquartile range of glucose level) in [mmol/l]. 
 Glycemic variability as measured by Mean Amplitude of Glycemic 
Excursions (MAGE), calculated according to the algorithm of 
Baghurst [17-18]. While there are many glycemic variability metrics 
described in the literature [19], MAGE was now chosen due to its 
very widespread use even in spite of its limitations [20], i.e. to show 
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a representative example of glycemic variability metrics to illustrate 
their application. Comparison of these metrics is extensively covered 
in the literature [21]. 
Summary of these parameters is presented in Table 2. 
2.2. Statistical analysis 
A pairwise analysis was performed between every possible variable 
(altogether 3·7=21 pairs). As every variable was quantitative, this was 
essentially a question of correlation, which was investigated with graphical 
(scatter plot) and analytical (calculation of correlation coefficients) methods. 
Scatter plots sometimes revealed not simply non-linear, but markedly non-
monotonic relationships, so the calculation of the linear correlation 
coefficients is not sufficient. Spearman-ρ correlation coefficient is often 
applied in situations where non-linearity is encountered [22], however it 
also falls short in detecting non-monotonic connections. Therefore, a 
method is needed that characterizes the overall dependence of two 
variables; now a modern metric for this purpose, called distance correlation 
[23-25] was used. Distance correlation is based on the difference between 
the joint probability density function of the variables and the product of 
their marginal density functions (as these should be equal if the variables are 
independent, hence, their difference characterizes the dependence of the 
variables). This way, distance correlation does not depend on the nature of 
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the relationship, it can detect the strength of linear and non-linear, 
monotonic and non-monotonic, i.e. arbitrary connection between the 
variables. 
Also to facilitate the detection of more complex connections, LOWESS-
estimators [26] for the non-parametric regression between the investigated 
variables were plotted on the scatter plots. Second-degree polynomial were 
used with a smoothing parameter of 0.75. Ninety-five percent confidence 
intervals for the regression are also shown. These non-parametric 
regressions – and their confidence intervals – help visualizing the 
relationship between the investigated variables (without confining ourselves 
to any pre-specified function form of the relationship). 
Due to the relatively low sample size, we did not attempt to perform an age-
stratified analysis, to maintain the reliability of the results. 
Statistical analysis and visualization was performed under the R statistical 
environment, version 3.0.2 [27]. The R script developed for this purpose is 
available at the corresponding author on request. 
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3. Results 
Age and duration of DM showed no clear relationship with any descriptor of 
the glucose levels as evidenced by the correlation coefficients (Table 3) and 
the scatterplots (figures not shown here). 
HbA1c (Figure 1) however shows a clear – but statistically non-significant – 
overall positive association with ratio of time spent in hyperglycemia (but 
not with hypoglycemia). Note that a small, seemingly paradoxical non-
monotonic region at about HbA1c=10% can be observed. As far as the 
central tendency is concerned, again a clear, but statistically non-significant 
overall positive association can be observed both for mean and median. The 
paradoxical non-monotonic region around 10% shows up again. However, 
for glycemic variability, there is a clear and statistically significant positive 
association (both for standard deviation and interquartile range). The trend 
change about 10% is not as pronounced as before; rather, a flat region can 
be seen on the scatter plots. 
MAGE (Figure 2) only has a slight positive association with HbA1c (and 
the paradoxical region around 10% is missing, too). 
Linear correlation coefficients are significant for glucose variability vs. 
HbA1c (p<0.005) and MAGE vs. HbA1c (p=0.0385). Time spent in 
hyperglycemia is at the border of significance. Distance correlations are 
significant likewise for variabilities (p=0.0165 and p=0.0063), and is at the 
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border of significance for MAGE (p=0.0676). Note that distance correlation 
is always between 0 and 1, as there is no point in talking about the direction 
of the relationship for a non-monotonic function. The p-values of the 
distance correlations are expected to be higher, given the fact that this test 
has lower power (due to its more general nature). 
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4. Discussion 
Duration of diabetes and age is not associated with any indicator of glucose 
evolution during CGM in clinically relevant way. On the other hand, HbA1c 
is positively – and statistically significantly – associated with the indicators 
of the variability of glucose levels and MAGE. Compared to the duration of 
diabetes and age, stronger and clinically relevant, but statistically still non-
significant, overall positive association can be observed between HbA1c 
and the indicators of the central tendency of glucose level and time spent in 
hyperglycemia. (Non-significance of these is likely attributable to the low 
sample size.) These associations – especially for the time spent in 
hyperglycemia and the central tendency of glucose levels – are not linear, 
furthermore not even monotonic, as they show a marked temporary decrease 
around HbA1c=10%. 
Note that as now 21 hypothesis testings were performed in parallel (one for 
each patient characteristic/CGM-property combination), results cannot be 
compared to the traditional threshold of 5% due to the multiple comparisons 
situation [28]. However, significant correlations – especially for variability 
– had magnitude smaller p-values, so labeling of these as significant 
association is justified, even in the light of the multiple comparisons 
situation. 
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The positive association between the indicators of the central tendency of 
glucose and HbA1c is well known, even quantitatively [29-31]. 
Positive association between the indicators of the variability and HbA1c are 
also described in the literature [32] but not with uniform results [33-34]. 
Our results also confirm the suggested [34] association between 
hyperglycemia and HbA1c. 
The explanation for the seemingly paradoxical behavior of the association 
of HbA1c with the various descriptors of glucose levels is possibly the poor 
adherence that is characteristic for most of the investigated children. The 
motivation to “cheat” during the CGM-measurements (i.e. to pay closer 
attention to glucose levels than it is usually done by the children) is higher 
for those having worse metabolic state (as evidenced by HbA1c higher than 
8%). Also, there is not only a motivation, but also a possibility for this, 
given that the measurements were non-blinded for the children. Hence, it 
may be hypothesized that children above 8% HbA1c start to increasingly 
pay unusual – i.e. that is not done without CGM – attention to their glucose 
levels during CGM measurement, breaking the association between HbA1c 
and the mean (or median) glucose during CGM. They could, however, do it 
only up to a point (about 10%) as even worse metabolic states could not be 
“compensated” by such temporarily increased adherence. This can be more 
directly illustrated when HbA1c is converted to (long-term) estimated 
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average glucose and is contrasted with the average glucose (i.e. short-term 
average) that can be calculated from the CGM recording (Figure 3). The 
conversion of HbA1c to estimated average glucose was done using the 
formula eAGmmol/l = 1.59 x HbA1c% – 2.59 [29]. 
This phenomenon is the well-known Hawthorne effect studied in many 
fields of science, and already described in relationship to CGM as well [35]. 
Hawthorne effect claims that patients – not necessarily deliberately – alter 
their behavior when they know that they are under observation. 
The small sample size and the convenience sampling of the present study 
limits the robustness of this conclusion, and further studies are needed to 
confirm this finding, and – if confirmed – investigate its determinants. 
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5. Conclusion 
The results confirmed the well-known positive association of HbA1c with 
the indicators of the central tendency of glucose (mean, median). No 
association was found between the duration of the diabetes and the age of 
the patient with any indicator of the glucose levels. 
The relationship between HbA1c and the indicators of the central tendency 
of glucose are non-monotonic, which is likely caused by the varying 
adherence of the patients. HbA1c was also positively associated with 
MAGE, but the non-monotonic region was missing, underlining MAGE’s 
usefulness in the reliable assessment of the patients’ glycemic state. 
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Title: Association of hyper- and hypoglycemia, central tendency and 
dispersion during CGM with HbA1c. 
Description: Scatterplots of HbA1c and the various descriptors of the CGM-
measured glucose profile. Solid line indicates the best fitting non-parametric 
regression curve obtained with LOWESS, gray shading shows 95% 





Title: Association of MAGE during CGM with HbA1c. 
Description: Scatterplot of HbA1c and MAGE of the CGM-measured 
glucose profile. Solid line indicates the best fitting non-parametric 
regression curve obtained with LOWESS, gray shading shows 95% 




Title: Estimated average glucose calculated from HbA1c (i.e. long-term 
average) vs. average glucose during CGM (i.e. short-term average). 
Description: Scatterplot of estimated average glucose calculated from 
HbA1c and average glucose during CGM. Dashed line indicates the best 
fitting non-parametric regression curve obtained with LOWESS, gray 
shading shows 95% confidence interval for this curve. Solid line is the 







Title: Most important descriptive statistics of the patients’ characteristics. 
Description: Patient characteristics in Mean (Median) ± SD (IQR) [Min-
Max] format for continuous variables and as frequency tables for discrete 
variables. 
Parameter Descriptive statistics 
Total number of patients 57 
Treatment regime 30 (52.6%) MDI, 27 (47.4%) insulin pump 
Length of CGM measurement [hours] 216.9 (161.6) ± 166.7 (258.1) [19.5 – 705.5] 
Type of device 47 (82.5%) Guardian REAL-Time 
9 (15.8%) Paradigm 522 and 722 
1 (1.8%) Paradigm Veo-554 
Sex 36 (63.2%) female, 21 (36.8%) male 
Age [year] 12.5 (13.0) ± 3.5 (6.0) [4 – 18] 
Duration of DM [year] 5.1 (4.0) ± 3.5 (6.0) [1 – 18] 
HbA1c [%] 8.6 (8.2) ± 1.5 (1.7) [5.9 – 12.1] 




Title: Most important descriptive statistics of the investigated CGM 
parameters. 
Description: Descriptive statistics of the indicators derived from CGM-
measured glucose evolution in Mean (Median) ± SD (IQR) [Min-Max] 
format. 
Parameter Descriptive statistics 
Percentage of time spent in hyperglycemia 
(>10 mmol/l) [%] 
31.3 (30.8) ± 16.3 (21.7) [0.4-74.3] 
Percentage of time spent in hypoglycemia 
(<3.9 mml/l) [%] 
1.1 (0.5) ± 1.4 (1.3) [0-4.7] 
Mean glucose level [mmol/l] 8.8 (8.8) ± 1.23 (1.49) [5.97-12.04] 
Median glucose level [mmol/l] 8.42 (8.3) ± 1.38 (1.9) [4.7-11.7] 
Glucose level standard dev. [mmol/l] 2.75 (2.8) ± 0.59 (0.62) [1.18-4.09] 
Glucose level IQR [mmol/l] 3.85 (3.9) ± 1.01 (1.1) [1.4-6.65] 
MAGE 7.17 (7.39) ± 1.47 (1.89) [3.46-9.65] 
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Table 3 
Title: Correlation of the investigated parameters. 
Description: Asymmetric correlation matrix of the investigated parameters (linear and distance correlation coefficients with significance). 
 













Ratio of hyperglycemia (>10 mmol/l) [%] 
r 0.04 -0.01 0.24 0.21 0.18 0.27 
p 0.7403 0.9514 0.0775 0.5540 0.7953 0.1642 
Ratio of hypoglycemia (<3.9 mml/l) [%] 
r -0.04 0.02 -0.14 0.15 0.18 0.24 
p 0.7801 0.8723 0.2871 0.8881 0.5777 0.1929 
Mean glucose level [mmol/l] 
r 0.05 0.03 0.21 0.22 0.20 0.26 
p 0.7226 0.8291 0.1200 0.4637 0.6394 0.1904 
Median glucose level [mmol/l] 
r 0.02 0.04 0.14 0.20 0.20 0.23 
p 0.8567 0.7689 0.2855 0.6163 0.5904 0.3482 
Glucose level standard deviation [mmol/l] 
r 0.13 -0.15 0.38 0.22 0.22 0.36 
p 0.3467 0.2730 0.0032 0.4869 0.4757 0.0165 
Glucose level IQR [mmol/l] 
r 0.09 -0.08 0.42 0.17 0.22 0.39 
p 0.4881 0.5497 0.0013 0.9606 0.5756 0.0063 
MAGE 
r 0.10 -0.17 0.27 0.19 0.25 0.30 
p 0.4727 0.1989 0.0385 0.7057 0.2390 0.0676 
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